PHXM
PHAXIAM Therapeutics S.A.
NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY
$3.10
+0.00% today
Updated 2026-05-01
Market cap
$28.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-39.05
Dividend yield
—
52W range
$0 – $0
Volume
—
PHAXIAM Therapeutics S.A. (PHXM) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.10
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$4.22
Financial forecast
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -191.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.